Coherus Oncology (NASDAQ:CHRS) Issues Earnings Results

Coherus Oncology (NASDAQ:CHRS) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.05, FiscalAI reports. Coherus Oncology had a net margin of 397.30% and a negative return on equity of 198.90%. The business had revenue of $14.31 million for the quarter, compared to analyst estimates of $14.41 million.

Here are the key takeaways from Coherus Oncology’s conference call:

• LOQTORZI sales increased 15% quarter over quarter to $13.6 million, supported by the highest number of new patient starts since launch, lower discontinuations, and gradually improving treatment duration. Management reiterated its 2026 revenue outlook of $57 million to $62 million and expects average quarterly growth of 10% to 15%.
• Tagmokitug studies in head and neck cancer and colorectal cancer, along with the casdozokitug first-line HCC study, have completed enrollment. Early, immature data in PD-1-resistant head and neck cancer showed manageable safety and signs of activity, potentially enriched among HPV-positive patients and those with higher TIRI scores; a formal update is expected in October.
• Casdozokitug HCC data are expected in the fourth quarter, but the study remains relatively immature, with only about half of patients having received three scans. Management said it may not need to wait for overall-survival data to decide on a potential Phase III program, while emphasizing response durability, clinical benefit rate, ctDNA, and IL-27 biomarkers.
• Cash, cash equivalents, and investments declined to $105.3 million from $167 million in the prior quarter, primarily because of $39 million in transition-service-agreement obligations. The company said it remains funded through key 2026–2027 readouts, but the $37.5 million Q2 UDENYCA divestiture milestone was not achieved, subject to final buyer-result adjustments.
• Continuing-operations R&D and SG&A expenses fell year over year, and the company expects full-year 2026 operating expenses of $170 million to $175 million. Legacy biosimilar liabilities also declined substantially and are expected to be largely settled by year-end.

Coherus Oncology Trading Down 2.0%

NASDAQ:CHRS traded down $0.03 during trading hours on Wednesday, hitting $1.45. The company had a trading volume of 992,580 shares, compared to its average volume of 1,522,866. The stock has a 50-day moving average price of $1.47 and a 200 day moving average price of $1.67. The company has a market capitalization of $223.66 million, a PE ratio of 0.87 and a beta of 0.98. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.56 and a quick ratio of 1.52. Coherus Oncology has a 52 week low of $0.81 and a 52 week high of $2.62.

Analyst Ratings Changes

A number of analysts have recently weighed in on CHRS shares. Guggenheim assumed coverage on shares of Coherus Oncology in a report on Monday, May 11th. They set a “buy” rating and a $12.00 target price for the company. Weiss Ratings upgraded Coherus Oncology from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 13th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.67.

Institutional Trading of Coherus Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. boosted its position in Coherus Oncology by 45.6% during the 4th quarter. Invesco Ltd. now owns 380,033 shares of the biotechnology company’s stock valued at $540,000 after acquiring an additional 119,041 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Coherus Oncology by 71.6% during the 4th quarter. XTX Topco Ltd now owns 166,797 shares of the biotechnology company’s stock worth $237,000 after acquiring an additional 69,621 shares during the period. Millennium Management LLC bought a new position in shares of Coherus Oncology in the 4th quarter worth approximately $938,000. Bridgeway Capital Management LLC lifted its stake in shares of Coherus Oncology by 72.9% in the 4th quarter. Bridgeway Capital Management LLC now owns 441,000 shares of the biotechnology company’s stock valued at $626,000 after purchasing an additional 186,000 shares during the period. Finally, Blair William & Co. IL purchased a new position in shares of Coherus Oncology in the 4th quarter valued at approximately $27,000. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.